GlassScriptPhysician profile
James A Evanson
NPI 1093715435
$21,307.55
in general payments reported to CMS, 2019-2025
23 companies · $5,073 in 2025
The $5,073 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $142 · 2021: $675 · 2022: $2,461 · 2023: $2,051 · 2024: $10K · 2025: $5,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,390 · Travel and Lodging: $3,005 · Education: $92.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,128.00 |
| Food and Beverage | $3,389.56 |
| Travel and Lodging | $3,005.05 |
| Education | $92.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17,261.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $752.88 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $740.39 | 2021-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $519.57 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $255.55 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $242.27 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $233.66 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $211.78 | 2023-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $193.14 | 2019-2024 | Korsuva, Veltassa |
| Amgen INC. | $140.92 | 2019-2025 | Tavneos |
| Ardelyx, INC. | $121.45 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Janssen Pharmaceuticals, INC | $111.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $110.68 | 2021-2025 | |
| Kyowa Kirin, INC. | $93.59 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.42 | 2024-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62.75 | 2022-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $62.60 | 2021-2024 | |
| Lundbeck LLC | $22.72 | 2019 | |
| Daiichi Sankyo INC. | $17.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.87 | 2024 | Crysvita |
| Opko Pharmaceuticals, LLC | $16.30 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.38 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Evanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.